Seeking Alpha

Eli Lilly (LLY -4.65%) shares are taking a hit this morning after the FDA delayed approving a...

Eli Lilly (LLY -4.65%) shares are taking a hit this morning after the FDA delayed approving a diabetes treatment in the final stages of development in order to further study a safety issue. The surprise move is also bleeding shares of partners Amylin (AMLN -51.4%) and Alkermes (ALKS -27.2%).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)